

PURICORE PLC

NOTICE OF ANNUAL GENERAL MEETING

Notice is hereby given that the Annual General Meeting of PuriCore plc (the "Company") will be held at the offices of CMS Cameron McKenna LLP, Mitre House, 160 Aldersgate Street, London EC1A 4DD on 26 June 2013 at 10.00 a.m. to consider and, if thought fit, pass the following resolutions:

Ordinary Resolutions

1. To receive the audited accounts for the year ended 31 December 2012, the Directors' report on the accounts and the Auditor's report on the accounts.
2. To approve the Directors' Remuneration Report for the year ended 31 December 2012.
3. To re-elect Mr Birkett as a Director.
4. To re-elect Mr Hegglin as a Director.
5. To re-elect Mr Larkin as a Director.
6. To re-elect Mr Spicer as a Director.
7. To re-elect Ms Thorell as a Director.
8. To re-appoint KPMG Audit Plc as Auditor of the Company to hold office until the conclusion of the next general meeting at which audited accounts are laid before the Company.
9. To authorise the Directors to determine the remuneration of the Auditor.
10. To approve the PuriCore plc Value Creation Plan (the "VCP") and to authorise the Directors to do all acts and things necessary to establish and carry the VCP into effect.
11. To authorise the Directors generally and unconditionally pursuant to section 551 of the Companies Act 2006 to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company (together "relevant securities") up to an aggregate nominal amount of £3,340,694 comprising:
 - a. an aggregate nominal amount of £1,670,347, whether in connection with the same offer or issue as under (b) below or otherwise; and
 - b. an aggregate nominal amount of £1,670,347 in the form of equity securities (within the meaning of section 560(1) of the Companies Act 2006) in connection with an offer or issue by way of rights, open for acceptance for a period fixed by the Directors, to holders of ordinary shares (other than the Company) on the register on any record date fixed by the Directors in proportion (as nearly as may be) to the respective number of ordinary shares held by them, subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements, legal or practical problems arising in any overseas territory, the requirements of any regulatory body or stock exchange or any other matter whatsoever,

such authority to expire (unless renewed, varied or revoked by the Company in general meeting) on the earlier of fifteen months from the date this resolution is passed and the conclusion of the Annual General Meeting of the Company to be held in 2014, except that the Company may before such expiry make any offer or agreement that would or might require relevant securities to be allotted after such expiry and the Directors may allot relevant securities pursuant to any such offer or agreement as if such authority had not expired.

Special Resolutions

12. To empower the Directors pursuant to section 570 of the Companies Act 2006 to allot equity securities (as defined in section 560(1) of that Act) for cash pursuant to the general authority conferred on them by resolution 11 above as if section 561(1) of that Act did not apply to any such allotment, provided that this power shall be limited to:
 - a. any such allotment of equity securities in connection with an offer or issue by way of rights or other pre-emptive offer or issue, open for acceptance for a period fixed by the Directors, to holders of ordinary shares (other than the Company) on the register on any record date fixed by the Directors in proportion (as nearly as may be) to the respective number of ordinary shares held by them, subject to such exclusions or other arrangements as the Directors may

deem necessary or expedient in relation to fractional entitlements, legal or practical problems arising in any overseas territory, the requirements of any regulatory body or stock exchange or any other matter whatsoever; and

- b. any such allotment, otherwise than pursuant to paragraph (a) above, of equity securities having, in the case of ordinary shares, an aggregate nominal value or, in the case of other equity securities, giving the right to subscribe for or convert into ordinary shares having an aggregate nominal amount, not exceeding the sum of £501,104.

This authority shall expire, unless previously revoked or renewed by the Company in general meeting, at such time as the general authority conferred on the Directors by resolution 11 above expires, except that the Company may at any time before such expiry make any offer or agreement that would or might require equity securities to be allotted after such expiry and the Directors may allot equity securities in pursuance of such an offer or agreement as if the power conferred by this resolution had not expired.

13. To authorise the Directors to call a general meeting of the Company, other than an Annual General Meeting, on not less than 14 clear days' notice.

By order of the Board:

Marella Thorell
Company Secretary

Registered Office
Wolseley House
Staffordshire Technology Park
Beaconside, Stafford
ST18 0GA

24 May 2013

Inspection of documents

The following documents will be available for inspection at the offices of CMS Cameron McKenna LLP, Mitre House, 160 Aldersgate Street, London EC1A 4DD from 15 minutes before the AGM until it ends: copies of the Executive Directors' service contracts and copies of letters of appointment of the Non-Executive Directors. In addition, the rules of the PuriCore plc Value Creation Plan will be available for inspection at the same address during normal business hours (except Saturdays, Sundays and public holidays) from the date of this document up to the conclusion of the AGM and at the AGM itself.

Notes:

1. A member who is an individual is entitled to attend, speak and vote at the meeting or to appoint one or more other persons as his/her proxy to exercise all or any of his/her rights on his/her behalf. Further details of how to appoint a proxy, and the rights of proxies, are given in the paragraphs below. A member that is a company can appoint one or more corporate representatives (such as a director or employee of the company) whose attendance at the meeting is treated as if the company were attending in person, or it can appoint one or more persons as its proxy to exercise all or any of its rights on its behalf. In each case, a person attending the meeting will need to provide the Company or its registrars, Equiniti Limited, with evidence of their identity and, if applicable, their appointment as a proxy or corporate representative with authority to vote on behalf of a member.
2. A shareholder may appoint more than one proxy in relation to the Annual General Meeting provided that each proxy is appointed to exercise the rights attached to a different share or shares held by that shareholder. A proxy need not be a shareholder of the Company. To appoint a proxy or proxies shareholders must: (a) complete a Form of Proxy, sign it and return it, together with the power of attorney or other authority (if any) under which it is signed, to the Company's registrars, Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA; (b) complete a CREST Proxy Instruction (as set out in paragraph 11 below); or (c) register the appointment of a proxy electronically at www.sharevote.co.uk (see paragraph 13 below), in each case so that it is received no later than 10.00 a.m. on 24 June 2013. To appoint more than one proxy, you will need to complete a separate Form of Proxy in relation to each appointment. A Form of Proxy for use in connection with the Annual General Meeting is enclosed with this document. If you do not have a Form of Proxy and believe that you should, please contact the Company's registrars, Equiniti Limited on 0871 384 2030* (or, if calling from overseas, on

+44 121 415 7047) or at Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA.

3. Where more than one proxy is being appointed, you will need to state clearly on each Form of Proxy the number of shares in relation to which the proxy is appointed. A failure to specify the number of shares each proxy appointment relates to or specify a number of shares in excess of those held by the member will invalidate the proxy appointment.
4. The return of a completed Form of Proxy or any CREST Proxy Instruction (as described in paragraph 11 below) will not prevent a shareholder attending the Annual General Meeting and voting in person if he/she wishes to do so.
5. In the case of joint holders, where more than one of the joint holders purports to appoint a proxy, only the appointment submitted by the most senior holder will be accepted. Seniority is determined by the order in which the names of the joint holders appear in the Company's register of members in respect of the joint holding (the first-named being the most senior).
6. Any person to whom this Notice is sent who is a person nominated under section 146 of the Companies Act 2006 to enjoy information rights (a "Nominated Person") may, under an agreement between him/her and the shareholder by whom he/she was nominated, have a right to be appointed (or to have someone else appointed) as a proxy for the Annual General Meeting. If a Nominated Person has no such proxy appointment right or does not wish to exercise it, he/she may, under any such agreement, have a right to give instructions to the shareholder as to the exercise of voting rights.
7. The statement of the rights of shareholders in relation to the appointment of proxies in paragraphs 1, 2 and 3 above does not apply to Nominated Persons. The rights described in these paragraphs can only be exercised by shareholders of the Company.
8. Pursuant to regulation 41 of the Uncertificated Securities Regulations 2001, the Company gives notice that only those shareholders included in the register of members of the Company at 6.00 p.m. on 24 June 2013 or, if the meeting is adjourned, in the register of members at 6.00 p.m. on the day that is two days before the day of any adjourned meeting, will be entitled to attend and to vote at the Annual General Meeting in respect of the number of shares registered in their names at that time. Changes to entries on the share register after 6.00 p.m. on 24 June 2013, or, if the meeting is adjourned, in the register of members at 6.00 p.m. on the day that is two days before the day of any adjourned meeting, will be disregarded in determining the rights of any person to attend or vote at the Annual General Meeting.
9. As at 22 May 2013, the Company's issued share capital comprised 50,110,432 ordinary shares of 10 pence each. Each ordinary share carries the right to one vote at a general meeting of the Company and, therefore, the total number of voting rights in the Company as at 22 May 2013 is 50,110,432.
10. CREST members who wish to appoint a proxy or proxies through the CREST electronic proxy appointment service may do so for the Annual General Meeting and any adjournment(s) of the meeting by using the procedures described in the CREST Manual (available via www.euroclear.com/CREST). CREST personal members or other CREST sponsored members, and those CREST members who have appointed a service provider(s), should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf.
11. In order for a proxy appointment or instruction made using the CREST service to be valid, the appropriate CREST message (a "CREST Proxy Instruction") must be properly authenticated in accordance with Euroclear UK & Ireland Limited's specifications, and must contain the information required for such instruction, as described in the CREST Manual. The message, regardless of whether it constitutes the appointment of a proxy or is an amendment to the instruction given to a previously appointed proxy must, in order to be valid, be transmitted so as to be received by the Company's agent (ID RA19), by the latest time for receipt of proxy appointments set out in paragraph 2 above. For this purpose, the time of receipt will be taken to be the time (as determined by the timestamp applied to the message by the CREST Applications Host) from which the Company's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. After this time any change of instructions to proxies appointed through CREST should be communicated to the appointee through other means.

12. CREST members and, where applicable, their CREST sponsors, or voting service providers should note that Euroclear UK & Ireland Limited does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will, therefore, apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member, or sponsored member, or has appointed any voting service provider(s), to procure that his CREST sponsor or voting service provider(s) take(s) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting service providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings.
13. You may, if you wish, register the appointment of a proxy electronically by visiting www.sharevote.co.uk. To use this service you will need your Voting ID, Task ID and Shareholder Reference Number printed on the accompanying Form of Proxy. Full details of the procedure are given on the website at www.sharevote.co.uk.
14. Under section 527 of the Companies Act 2006 members meeting the threshold requirements set out in that section have the right to require the Company to publish on a website a statement setting out any matter relating to: (i) the audit of the Company's accounts (including the auditor's report and the conduct of the audit) that are to be laid before the Annual General Meeting; or (ii) any circumstance connected with an auditor of the Company ceasing to hold office since the previous meeting at which annual accounts and reports were laid in accordance with section 437 of the Companies Act 2006. The Company may not require the shareholders requesting any such website publication to pay its expenses in complying with sections 527 or 528 of the Companies Act 2006. Where the Company is required to place a statement on a website under section 527 of the Companies Act 2006, it must forward the statement to the Company's auditor not later than the time when it makes the statement available on the website. The business that may be dealt with at the Annual General Meeting includes any statement that the Company has been required under section 527 of the Companies Act 2006 to publish on a website.
15. Any member attending the meeting has the right to ask questions. The Company must answer any such question relating to the business being dealt with at the meeting but no such answer need be given if (a) to do so would interfere unduly with the preparation for the meeting or involve the disclosure of confidential information, (b) the answer has already been given on a website in the form of an answer to a question, or (c) it is undesirable in the interests of the Company or the good order of the meeting that the question be answered.
16. You may not use any electronic address provided in this Notice, or any related documents including the Form of Proxy, to communicate with the Company for any purposes other than those expressly stated.
17. A copy of this Notice, and other information required by section 311A of the Companies Act 2006, can be found at www.puricore.com.
** Calls to this number are charged at 8p per minute plus network extras. Lines are open 8.30 a.m. to 5.30 p.m., Monday to Friday.*

Explanatory Notes

Resolution 1 – Presentation of Accounts

The Directors are required by the Companies Act 2006 to present to the shareholders of the Company at a general meeting the reports of the Directors and Auditor and the audited accounts for the year ended 31 December 2012.

Resolution 2 – Directors' Remuneration Report

The Companies Act 2006 requires the Company to seek shareholder approval for the Directors' Remuneration Report at the general meeting before which the Company's annual accounts are presented.

Resolutions 3 through 7 – Re-election of Directors

In accordance with the Company's Articles of Association, Mr Hegglin, who was appointed by the Board as a non-executive Director in January 2013, Ms Thorell, who was appointed to the Board as

Finance Director/Chief Financial Officer in March 2013, Mr Larkin, who was appointed by the Board as an independent non-executive Director in April 2013, and Mr Spicer who has been appointed by the Board as an independent non-executive Director with effect from 1 June 2013, will be retiring at the Annual General Meeting and, being eligible, will offer themselves for re-election at the Annual General Meeting.

In addition, under the UK Corporate Governance Code, Mr Birkett, having served as a Director for more than nine years, will be retiring at the Annual General Meeting and, being eligible, will offer himself for re-election at the Annual General Meeting.

The Directors unanimously recommend that Mr Birkett, Mr Hegglin, Mr Larkin, Mr Spicer and Ms Thorell be re-elected as Directors of the Company. The Directors are satisfied that each of the Directors and Mr Spicer shows the necessary commitment to the Company and has the necessary skills, expertise and business acumen to be an effective member of the Board.

Short biographical details of Mr Birkett, Mr Hegglin, Mr Larkin and Ms Thorell are set out on page 5 of the Annual Report of the Company for the year ended 31 December 2012.

The Company announced on 14 May 2013 that Mr Spicer is to be appointed as a Director with effect from 1 June 2013. Mr Spicer has more than 15 years of experience working with the healthcare sector and specifically the medtech segment. He advises medtech and life sciences companies on corporate strategy, M&A and corporate finance. Mr Spicer is a non-executive director of Aircraft Medical, Stanmore Implants, Ark Therapeutics Group plc, and XCounter AB. He is chair of the UK Department of Health's Invention for Innovation Funding Panel, a panel member on the UK Health Innovation Challenge Fund, and a member of the techMARK Advisory Group at the London Stock Exchange. Previously, Mr Spicer served as chief executive and a director of MDY Healthcare plc, an AIM-quoted strategic investment company focused on medtech and prior to that as head of healthcare at Numis Securities and Nomura International.

Resolutions 8 and 9 – Auditor's re-appointment and remuneration

These resolutions seek shareholder approval for the re-appointment of KPMG Audit Plc as Auditor and also give the Directors the authority to determine their remuneration.

Resolution 10 – Value Creation Plan

This resolution seeks shareholder approval for the Value Creation Plan, the principal terms of which are summarised in the accompanying letter from the Chairman of the Remuneration Committee and the rules of which are produced to the Annual General Meeting and initialled by the Chairman of the Remuneration Committee for the purposes of identification; and also gives the Directors authority to establish and carry the Value Creation Plan into effect.

Resolution 11 – Authority to the Directors to allot shares

The Companies Act 2006 provides that the Directors may only allot shares if authorised by shareholders to do so. Resolution 11 will, if passed, authorise the Directors to allot shares up to a maximum nominal amount of £3,340,694, which represents an amount approximately equal to two thirds of the aggregate of the issued share capital of the Company as at 22 May 2013 (the latest practicable date prior to the publication of this Notice).

As provided in paragraph (a) of the resolution, up to half of the authority (equal to the first one-third) will enable Directors to allot and issue new shares in whatever manner (subject to pre-emption rights) they see fit. Paragraph (b) of the resolution provides that the remainder of the authority (equal to a further one-third) may only be used in connection with a rights issue in favour of ordinary shareholders. As paragraph (a) imposes no restrictions on the way the authority may be exercised, it could be used in conjunction with paragraph (b) so as to enable the whole two-thirds authority to be used in connection with a rights issue. Where usage of the authority exceeds the one-third threshold in the circumstances set out in the guidance issued by the Association of British Insurers (the "ABI") the Directors will stand for re-election at the following AGM, to the extent required by the ABI.

The authority will expire at the earlier of the date that is fifteen months after the date of the passing of the resolution and the conclusion of the next Annual General Meeting of the Company.

Passing resolution 11 will ensure that the Directors continue to have the flexibility to act in the best interests of shareholders, when opportunities arise, by issuing new shares. There are no current

plans to issue new shares except in connection with employee share schemes, the VCP warrants or in respect of convertible securities that have been issued by the Company which remain outstanding.

As at 22 May 2013, the latest practicable date prior to the publication of this Notice, the Company had 50,110,432 ordinary shares of 10 pence each in issue. No shares are held in treasury.

Resolution 12 – Partial disapplication of statutory pre-emption rights

The Companies Act 2006 requires that, if the Company issues new shares for cash, it must first offer them to existing shareholders in proportion to their current holdings. It is proposed that the Directors be authorised to issue shares for cash without offering them to shareholders first up to an aggregate nominal amount of £501,104 (representing approximately 10% of the aggregate of the issued share capital of the Company as at 22 May 2013 (the latest practicable date prior to the publication of this Notice)) and to modify statutory pre-emption rights to deal with legal, regulatory or practical problems that may arise on a rights or other pre-emptive offer or issue.

The Directors consider this authority necessary in order to give them flexibility to deal with opportunities as they arise, subject to the restrictions contained in the resolution and highlight the following factors, which they consider to be relevant to their recommendation to vote in favour of resolution 12:

- a. stock markets for bioscience companies can be extremely volatile and opportunities for equity fundraising can open and close very quickly. The prescribed period of time for which pre-emptive issues must remain open can prejudice the ultimate success of an issue and invariably expose the share price to downward pressure; and
- b. the authority could be used, for example, to issue equity for cash to invest in a focused and timely manner for specific opportunities for progressing development or commercialisation of one or more of the Company's products. This would enable the commercial value of those products to be enhanced and further the Company's overall strategic objective to continue to add shareholder value.

In keeping with the Company's policy of open and clear communication with shareholders, the Company would consult with major shareholders ahead of any issue of equity on a non pre-emptive basis.

Resolution 13 – Notice of General Meetings

In order to preserve flexibility to call general meetings (other than an Annual General Meeting) on 14 clear days' notice, the Company must offer all shareholders the opportunity to appoint a proxy electronically (via the website of the Company or its registrars) and must obtain the approval of its shareholders by means of a special resolution passed each year. Resolution 13 seeks such approval. It is intended that a similar resolution will be proposed at future Annual General Meetings. It is intended that this flexibility will only be used for non-routine business and where merited in the interests of shareholders as a whole.

Directors' Recommendation

Resolutions 1 to 11 are proposed as ordinary resolutions. This means that, for each of those resolutions to be passed, more than half of the votes cast must be in favour of the resolution. Resolutions 12 and 13 are proposed as special resolutions. This means that, for each of those resolutions to be passed, at least three-quarters of the votes cast must be in favour of the resolution.

The Directors consider all of the resolutions set out in the Notice of Annual General Meeting and explained above to be in the best interests of the Company and its shareholders as a whole. The Directors will be voting in favour of them and unanimously recommend that shareholders do so as well.

